drugset / Trial / NCT03122509
A Clinical Trial of Durvalumab and Tremelimumab, Administered With Radiation Therapy or Ablation in Patients With Colorectal Cancer
Phase 2
Completed
25 enrolled
Memorial Sloan Kettering Cancer Center
AstraZeneca · collabMedImmune LLC · collab
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to test the safety and effectiveness of two investigational drugs (drugs that are not currently approved by the FDA) given in combination with radiation therapy or ablation.
Timeline
- Start
- 2017-04-24
- Primary completion
- 2021-04-28
- Completion
- 2021-04-28
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Durvalumab | Monoclonal antibody | 1500 mg | Intravenous |
| Subject | Tremelimumab | Monoclonal antibody | 75 mg | Intravenous |